Melanoma 

  • S1801: Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
  • EA6134: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  • S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent

For more information, contact Mia Johnson, 360-788-8240